PHTALOX® Mouthwash as An Option to Reduce Clinical Symptoms of COVID-19: Case Series
6 Pages Posted: 25 Nov 2020
Date Written: November 13, 2020
Background: The PHTALOX® mouthwash appears in this case series as a promising alternative for reducing the viral load of SARS-CoV-2 and for clinical improvement of infected patients.
Objectives: The aim of this study was to report a case series of mouthwash to reduce clinical symptoms in patients diagnosed with COVID-19.
Methods: Eight patients used 5ml of PHTALOX® mouthwash for gargling/rinsing during 1 minute/ five times a day during 14 days. Two measurement scales were applied for each patient in different periods to verify sore throat - VAS – Visual Analogic Scale for Pain and the clinical conditions - PS – Performance Status.
Results: All patients presented a significant reduction in clinical symptoms with PHTALOX® mouthwash for gargling/rinsing after few days of use, without hospitalization.
Conclusion: The PHTALOX® mouthwash protocol appears as a promising alternative for clinical improvement of COVID-19 infected patients. Daily use of this mouthwash rapidly reduced clinical symptoms such as sore throats, coughs and mouth ulcers. Clinical trials are necessary to confirm the effectiveness of PHTALOX® protocol against COVID-19.
Note: Funding: This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil (Finance Code 001).
Declaration of Interests: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Vilhena reports personal fees from TRIALS Inc, during the conduct of the study; In addition, Dr. Vilhena has a patent classified pending. Dr. Araki reports grants from CNPq 401581/2016-0, grants from FAPESP 18/21489-1, during the conduct of the study; In addition, Dr. Araki has a patent null pending. Dr. DA SILVA SANTOS reports personal fees and other from null, during the conduct of the study; other from null, outside the submitted work. The other authors claim there are no conflicts of interest.
Ethics Approval Statement: Approved by ethics committee - 36493520.1.0000.5417
Keywords: mouthwash; sore throats; mouth ulcers; coronavirus infections
JEL Classification: I
Suggested Citation: Suggested Citation